Current Status and Future Directions for Immunotherapy in Hepatocellular Carcinoma

Learn how to leverage immune checkpoint inhibitors for optimal management of HCC across different settings with expert-authored slides and an on-demand Webcast capturing a dynamic, live CCO Webinar.
Ghassan K. Abou-Alfa, MD, MBA
Program Director
Ghassan K. Abou-Alfa, MD, MBA
Peter R. Galle, MD, PhD
Bruno Sangro, MD, PhD

Downloadable Slidesets

Download this slideset from Bruno Sangro, MD, PhD, to see the latest data on immunotherapy treatment options for patients with hepatocellular carcinoma.

Bruno Sangro, MD, PhD Released: October 14, 2020

Download this slideset from Ghassan K. Abou-Alfa, MD, MBA, to see the latest data on first-line immunotherapy treatment options for patients with advanced hepatocellular carcinoma.

Ghassan K. Abou-Alfa, MD, MBA Released: October 14, 2020

Download this slideset from Peter R. Galle, MD, PhD, to see the latest data on immunotherapy treatment options for patients with early or intermediate-stage hepatocellular carcinoma.

Peter R. Galle, MD, PhD Released: October 14, 2020

On-Demand Webcast

Get up to date on how European experts leverage immune checkpoint inhibitor–based therapy to optimally treat patients with early-stage through metastatic hepatocellular carcinoma.

Ghassan K. Abou-Alfa, MD, MBA
Program Director
Peter R. Galle, MD, PhD Bruno Sangro, MD, PhD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: October 26, 2020 Expired: October 25, 2021
Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
AstraZeneca

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue